Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human blood coagulation factor VIII - Octapharma

Next Previous
Drug Profile

Human blood coagulation factor VIII - Octapharma

Alternative Names: Factor VIII/von Willebrand factor (VWF) concentrate - Octapharma; Octafil; Octafil LV; Octanate; Octanate Kons; Octanate LV

Latest Information Update: 19 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Octapharma
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 22 Jul 2020 Launched for Haemophilia A in Croatia, Uruguay, Turkey, Tunisia, Oman, Mexico, Macedonia, Indonesia, Georgia, Chile, Bosnia-Herzegovina, Argentina, Philippines (IV), before July 2020
  • 01 Jan 2017 Withdrawn for Haemophilia A in Greece (IV)
  • 14 Oct 2014 Octanate LV 100 IU/mL and 200 IU/mL launched for Haemophilia A in Cyprus, Czech Republic, Denmark, Sweden, Austria, Belgium, Estonia, Finland, France, Ireland, Italy, Latvia, Lithuania, Malta, Poland, Portugal, Romania, Greece, Slovenia, United Kingdom, after October 2014

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top